Check-Cap
51 articles with Check-Cap
-
Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results
3/19/2021
Received FDA IDE Approval for Pivotal Study of C-Scan® Company on track to initiate a U.S. pivotal study of C-Scan in late 2021
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Check-Cap Issues Letter to Shareholders
1/27/2021
Check-Cap Ltd., a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, issued the following letter from its chief executive officer, Alex Ovadia to its shareholders and the investment community:
-
Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
11/18/2020
Submitted Investigational Device Exemption (IDE) application to the FDA for Pivotal Study of C-Scan®
-
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
8/6/2020
IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.
-
Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
7/23/2020
Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.
-
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
6/5/2020
Check-Cap Ltd . (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan ® , the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a let
-
Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/27/2020
Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
-
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
5/9/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
4/30/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
4/20/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
4/6/2020
Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.
-
BioSpace Global Roundup, Jan. 2
1/2/2020
Companies from across the globe announce updates to their business and pipeline. -
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
12/30/2019
Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020
-
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
11/6/2019
Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System
-
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
10/24/2019
Check-Cap Ltd. announced that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the Dawson James 5th Annual Small Cap Growth Conference, being held October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.
-
BioSpace Movers & Shakers, Sept. 27
9/27/2019
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments. -
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
9/3/2019
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), announced today that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019 in New York.
-
BioSpace Global Roundup, Aug. 22
8/22/2019
Companies from across the globe provide updates on their business and pipelines. -
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
8/19/2019
GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.